Skip to main content
AAPL+0.69%NVDA-4.63%MSFT+1.52%GOOGL+2.17%AMZN+1.56%TSM-0.57%SPCX+2.75%AVGO+6.08%META-0.41%TSLA+0.16%LLY+0.77%BRK-B+0.81%SKHY-2.23%WMT+0.13%MU-2.22%JPM+0.57%AMD+7.09%V+0.23%XOM+0.95%JNJ+1.13%ASMLa-1.57%MA0.00%ABBV+0.52%COST+0.62%1398.HK-0.63%0700.HK-2.64%KO+0.26%CVX+1.08%CSCO+1.07%PG+0.48%ORCL+0.18%UNH+0.17%GE-1.18%0939.HK-0.57%HD+0.11%BAC+0.31%3988.HK+0.32%INTC+0.15%1816.HK+0.65%0857.HK-0.50%AMAT+0.28%0005.HK-0.64%AP2d-0.35%HSBA.L-0.11%PM+1.40%1288.HK-0.73%NVS+0.35%MS+0.33%LRCX+1.37%AZN-0.46%NZDCHF+1.81%USDCHF+1.69%USDZAR+1.02%NZDJPY+1.02%NZDCAD+0.99%USDTHB+0.99%EURCHF+0.98%GBPNZD-0.95%AUDCHF+0.92%USDCAD+0.90%USDJPY+0.90%AUDNZD-0.88%GBPUSD-0.83%GBPCHF+0.82%EURNZD-0.82%CADCHF+0.81%CHFJPY-0.80%EURZAR+0.79%GBPZAR+0.77%AUDUSD-0.76%EURUSD-0.71%GBPTRY+0.41%USDSEK+0.39%AUDNOK-0.37%AUDSGD-0.32%GBPHKD+0.32%GBPMXN-0.28%AUDDKK-0.27%USDTRY+0.25%EURPLN-0.24%CHFSEK+0.24%EURCNH-0.24%EURHKD-0.23%USDDKK+0.22%NZDMXN-0.20%EURJPY+0.19%EURCAD+0.18%USDSGD+0.17%EURSEK+0.17%USDILS+0.16%NZDUSD+0.16%EURGBP+0.15%AUDJPY+0.13%AUDCAD+0.12%USDNOK+0.12%EURNOK-0.11%SGDJPY-0.10%PLNJPY+0.09%GBPSGD-0.08%GBPAUD-0.08%USDHKD+0.06%EURAUD+0.06%EURSGD-0.06%NOKJPY-0.05%GBPJPY+0.04%USDCOP-0.04%GBPCAD+0.04%CHFNOK-0.03%CHFSGD+0.02%USDPLN-0.02%EURCZK+0.01%NZDSGD-0.01%CADJPY+0.01%USDMXN+0.01%EURDKK0.00%USDCNH0.00%COFFEE+3.24%GAGUSD-2.82%XAGUSD-2.82%GAUUSD-2.81%XAUUSD-2.81%SUGAR-1.84%XNGUSD+1.12%HG1-1.11%UKOIL+0.96%W1-0.93%XPTUSD-0.73%USOIL+0.42%BTCUSD-2.76%ETHUSD+40.05%USDTUSD+0.01%XRPUSD+42.66%SOLUSD+42.29%TRXUSDT-0.13%ZECUSDT+0.18%DOGEUSD+38.92%XMRUSDT-3.47%LINKUSD-1.72%XLMUSD-1.50%BCHUSDT-1.40%UNIUSD-2.68%LTCUSD+34.13%TONUSD+46.15%SUIUSD-2.61%HBARUSDT-2.73%TAOUSDT-2.69%AAVEUSD-5.52%ICPUSDT-0.73%DOTUSDT-0.94%ONDOUSDT-2.08%ARBUSDT-2.73%JUPUSDT+2.94%WLDUSDT-0.47%INJUSDT-0.70%ATOMUSDT+1.85%STXUSDT-4.58%PYTHUSDT+0.53%TIAUSDT+0.70%FETUSDT-1.29%SEIUSDT-2.79%IMXUSDT-2.06%OPUSDT-2.94%GRTUSDT-2.10%POLUSDT-2.22%WIFUSDT-1.55%IOTAUSDT+0.92%AXSUSDT-1.86%EOSUSDT-1.67%FARTCOINUSDT-2.54%DYDXUSDT-1.28%GALAUSDT-0.54%ORDIUSDT-1.12%NOTUSDT+1.27%RONINUSDT-7.68%AAPL+0.69%NVDA-4.63%MSFT+1.52%GOOGL+2.17%AMZN+1.56%TSM-0.57%SPCX+2.75%AVGO+6.08%META-0.41%TSLA+0.16%LLY+0.77%BRK-B+0.81%SKHY-2.23%WMT+0.13%MU-2.22%JPM+0.57%AMD+7.09%V+0.23%XOM+0.95%JNJ+1.13%ASMLa-1.57%MA0.00%ABBV+0.52%COST+0.62%1398.HK-0.63%0700.HK-2.64%KO+0.26%CVX+1.08%CSCO+1.07%PG+0.48%ORCL+0.18%UNH+0.17%GE-1.18%0939.HK-0.57%HD+0.11%BAC+0.31%3988.HK+0.32%INTC+0.15%1816.HK+0.65%0857.HK-0.50%AMAT+0.28%0005.HK-0.64%AP2d-0.35%HSBA.L-0.11%PM+1.40%1288.HK-0.73%NVS+0.35%MS+0.33%LRCX+1.37%AZN-0.46%NZDCHF+1.81%USDCHF+1.69%USDZAR+1.02%NZDJPY+1.02%NZDCAD+0.99%USDTHB+0.99%EURCHF+0.98%GBPNZD-0.95%AUDCHF+0.92%USDCAD+0.90%USDJPY+0.90%AUDNZD-0.88%GBPUSD-0.83%GBPCHF+0.82%EURNZD-0.82%CADCHF+0.81%CHFJPY-0.80%EURZAR+0.79%GBPZAR+0.77%AUDUSD-0.76%EURUSD-0.71%GBPTRY+0.41%USDSEK+0.39%AUDNOK-0.37%AUDSGD-0.32%GBPHKD+0.32%GBPMXN-0.28%AUDDKK-0.27%USDTRY+0.25%EURPLN-0.24%CHFSEK+0.24%EURCNH-0.24%EURHKD-0.23%USDDKK+0.22%NZDMXN-0.20%EURJPY+0.19%EURCAD+0.18%USDSGD+0.17%EURSEK+0.17%USDILS+0.16%NZDUSD+0.16%EURGBP+0.15%AUDJPY+0.13%AUDCAD+0.12%USDNOK+0.12%EURNOK-0.11%SGDJPY-0.10%PLNJPY+0.09%GBPSGD-0.08%GBPAUD-0.08%USDHKD+0.06%EURAUD+0.06%EURSGD-0.06%NOKJPY-0.05%GBPJPY+0.04%USDCOP-0.04%GBPCAD+0.04%CHFNOK-0.03%CHFSGD+0.02%USDPLN-0.02%EURCZK+0.01%NZDSGD-0.01%CADJPY+0.01%USDMXN+0.01%EURDKK0.00%USDCNH0.00%COFFEE+3.24%GAGUSD-2.82%XAGUSD-2.82%GAUUSD-2.81%XAUUSD-2.81%SUGAR-1.84%XNGUSD+1.12%HG1-1.11%UKOIL+0.96%W1-0.93%XPTUSD-0.73%USOIL+0.42%BTCUSD-2.76%ETHUSD+40.05%USDTUSD+0.01%XRPUSD+42.66%SOLUSD+42.29%TRXUSDT-0.13%ZECUSDT+0.18%DOGEUSD+38.92%XMRUSDT-3.47%LINKUSD-1.72%XLMUSD-1.50%BCHUSDT-1.40%UNIUSD-2.68%LTCUSD+34.13%TONUSD+46.15%SUIUSD-2.61%HBARUSDT-2.73%TAOUSDT-2.69%AAVEUSD-5.52%ICPUSDT-0.73%DOTUSDT-0.94%ONDOUSDT-2.08%ARBUSDT-2.73%JUPUSDT+2.94%WLDUSDT-0.47%INJUSDT-0.70%ATOMUSDT+1.85%STXUSDT-4.58%PYTHUSDT+0.53%TIAUSDT+0.70%FETUSDT-1.29%SEIUSDT-2.79%IMXUSDT-2.06%OPUSDT-2.94%GRTUSDT-2.10%POLUSDT-2.22%WIFUSDT-1.55%IOTAUSDT+0.92%AXSUSDT-1.86%EOSUSDT-1.67%FARTCOINUSDT-2.54%DYDXUSDT-1.28%GALAUSDT-0.54%ORDIUSDT-1.12%NOTUSDT+1.27%RONINUSDT-7.68%
JP

Jazz Pharmaceuticals plc (JAZZ)

NASDAQ • Healthcare

$248.24
+$2.81 (+1.1%)
Market open

Last close at November 11, 2026 at 21:00 UTC

Open$244.24
Previous Close$248.24
Day Range$243.76 - $248.97
Avg. Volume (3M)831.1K
Market Cap$15.6B
P/E Ratio69.3
52 Week Range
$136.56$266.38

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$1.2B100%
Gross Profitminus cost of goods$1.1B91%

In plain terms: out of every $100 in revenue, Jazz Pharmaceuticals plc currently loses $39.

Fundamentals & Financials

Revenue (TTM)
$4.7B
Net Income (TTM)
$205.9M
EPS (TTM)
$3.58
ROA (TTM)
1.72%
Current Ratio
1.82
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+36.6%Q2 2026$6.34
-7.6%Q3 2026$5.71
+3.7%Q4 2026-$3.88

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +3.7%

Jazz Pharmaceuticals’ preliminary third fiscal quarter of 2026 results showed revenue topping consensus, with sales up 10.4% year over year to about $1.2 billion (up from about $1.1 billion a year ago) as reported on November 2, 2026. On the top line, revenue of $1.243 billion topped the $1.208 billion estimate, +2.9%. The company generated about $506.1 million of operating cash flow during the quarter. Looking ahead, next-period consensus calls for EPS of $6.84 on revenue of $1.245 billion.

View full earnings history

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a biotechnology company listed on NASDAQ as JAZZ that develops and markets medicines for sleep disorders, epilepsy, and cancer across rare and specialty diseases. Its portfolio spans rare and specialty diseases, and the business generated $4.3 billion in FY2025 revenue.

Name
Jazz Pharmaceuticals plc
CEO
Renee D. Gala
Industry
Healthcare
Year Founded
2003
Employees
2,890

Today's Snapshot

AI-generated

JAZZ opened slightly higher at 248.80, while its sector was flat. Piper Sandler, an analyst, raised Jazz Pharmaceuticals’ price target to $330, citing its cancer drug Ziihera.

Trading Volume

Below 10d avg (854.0K)

92.5K

vs S&P 500 Today

Underperforming Market

-0.77%

Updated: November 12, 2026 at 15:56 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
Jazz displays a constructive technical picture with the stock trading well above most moving averages, including the 200-day level, while trend strength is solid as ADX is in the mid-30s. Momentum indicators are generally favorable—MACD and CCI are positive and RSI sits in bullish territory—while ATR suggests moderate volatility near 3% and OBV shows strong accumulation. The classic pivot sits above the current price as a nearby resistance level, but the broader tape favors buyers. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$213.77 - $235.14
    Buy
  • RSI (14)62.59
    Neutral
  • Stochastic %K (14, 3, 3)93.89
    Sell
  • MACD Level (12, 26)5.12
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.